Pharmamarketeer
onderzoek

Merck’s HIV therapy Delstrigo meets primary endpoint in phase 3 DRIVE─SHIFT trial

9 oktober 2018
Pharma Biz

Merck, known as MSD outside the United States and Canada, announced the first presentation of data from the phase 3 DRIVE─SHIFT trial evaluating a switch of medication to Delstrigo, a once─daily fixed─dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg), in adults with HIV-1 infection who demonstrated virological suppression for at least six months on a stable antiretroviral treatment regimen.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)